JP2023520405A5 - - Google Patents

Info

Publication number
JP2023520405A5
JP2023520405A5 JP2022559594A JP2022559594A JP2023520405A5 JP 2023520405 A5 JP2023520405 A5 JP 2023520405A5 JP 2022559594 A JP2022559594 A JP 2022559594A JP 2022559594 A JP2022559594 A JP 2022559594A JP 2023520405 A5 JP2023520405 A5 JP 2023520405A5
Authority
JP
Japan
Prior art keywords
compound according
compound
guanine
cytosine
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022559594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520405A (ja
JP7796038B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025019 external-priority patent/WO2021202621A2/en
Publication of JP2023520405A publication Critical patent/JP2023520405A/ja
Publication of JP2023520405A5 publication Critical patent/JP2023520405A5/ja
Priority to JP2025272734A priority Critical patent/JP2026048940A/ja
Application granted granted Critical
Publication of JP7796038B2 publication Critical patent/JP7796038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022559594A 2020-03-30 2021-03-30 改変ペプチド核酸組成物 Active JP7796038B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025272734A JP2026048940A (ja) 2020-03-30 2025-12-22 改変ペプチド核酸組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063002326P 2020-03-30 2020-03-30
US63/002,326 2020-03-30
PCT/US2021/025019 WO2021202621A2 (en) 2020-03-30 2021-03-30 Modified peptide nucleic acid compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025272734A Division JP2026048940A (ja) 2020-03-30 2025-12-22 改変ペプチド核酸組成物

Publications (3)

Publication Number Publication Date
JP2023520405A JP2023520405A (ja) 2023-05-17
JP2023520405A5 true JP2023520405A5 (cg-RX-API-DMAC7.html) 2024-08-20
JP7796038B2 JP7796038B2 (ja) 2026-01-08

Family

ID=77921451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022559594A Active JP7796038B2 (ja) 2020-03-30 2021-03-30 改変ペプチド核酸組成物
JP2025272734A Pending JP2026048940A (ja) 2020-03-30 2025-12-22 改変ペプチド核酸組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025272734A Pending JP2026048940A (ja) 2020-03-30 2025-12-22 改変ペプチド核酸組成物

Country Status (6)

Country Link
US (6) US20210309997A1 (cg-RX-API-DMAC7.html)
EP (1) EP4127228A4 (cg-RX-API-DMAC7.html)
JP (2) JP7796038B2 (cg-RX-API-DMAC7.html)
AU (1) AU2021246046A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173015A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021202621A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7796038B2 (ja) * 2020-03-30 2026-01-08 ニューベース セラピューティクス, インコーポレイテッド 改変ペプチド核酸組成物
CA3173504A1 (en) * 2020-12-15 2022-06-23 Dietrich A. Stephan Oligonucleotide analogue therapeutics for treatment of neuromuscular disease
WO2023244536A2 (en) * 2022-06-13 2023-12-21 Neubase Therapeutics, Inc. Oligonucleotide analogue formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080038783A1 (en) * 2006-06-29 2008-02-14 Applera Corporation Compositions and Methods Pertaining to Guanylation of PNA Oligomers
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー.フェー. Dnaリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
WO2008061091A2 (en) 2006-11-13 2008-05-22 Grandis Jennifer R Antisense guanidinium peptide nucleic acid (gpna) oligonucleotides as antitumor agents
AU2009276763B2 (en) * 2008-07-29 2015-07-16 The Board Of Regents Of The University Of Texas Sytem Selective inhibition of polyglutamine protein expression
WO2015172058A1 (en) 2014-05-08 2015-11-12 Carnegie Mellon University Left-handed gamma-peptide nucleic acids, methods of synthesis and uses therefor
CN111757935B (zh) * 2017-12-21 2025-02-21 卡耐基梅隆大学 二价核酸配体及其用途
WO2020172664A1 (en) * 2019-02-22 2020-08-27 Carnegie Mellon University Tuning binding cooperativity in nucleic acid targeting compounds
JP7796038B2 (ja) 2020-03-30 2026-01-08 ニューベース セラピューティクス, インコーポレイテッド 改変ペプチド核酸組成物

Similar Documents

Publication Publication Date Title
JP2020189864A5 (cg-RX-API-DMAC7.html)
JP2021100937A5 (cg-RX-API-DMAC7.html)
CN1116870C (zh) 司立吉林在制备用于预防或治疗外周神经病的药物中的应用
JP2023002662A5 (cg-RX-API-DMAC7.html)
JP2009508955A5 (cg-RX-API-DMAC7.html)
JP2022525149A5 (cg-RX-API-DMAC7.html)
JP2004502638A5 (cg-RX-API-DMAC7.html)
US20120027718A1 (en) Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
JPH06102622B2 (ja) 肥満の治療
CA2224119A1 (en) Method for treating multiple sclerosis
JP2005526833A5 (cg-RX-API-DMAC7.html)
JPWO2020004675A5 (cg-RX-API-DMAC7.html)
JP2023537921A5 (cg-RX-API-DMAC7.html)
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JPH0637395B2 (ja) ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤
RU2004131214A (ru) Способы лечения когнитивных расстройств
CN1750835A (zh) 治疗疼痛的化合物
JP2023548429A5 (cg-RX-API-DMAC7.html)
JP2023502053A5 (cg-RX-API-DMAC7.html)
JP2022501364A5 (cg-RX-API-DMAC7.html)
JP2019531286A5 (cg-RX-API-DMAC7.html)
JP2014522414A5 (cg-RX-API-DMAC7.html)
JP2024545496A5 (cg-RX-API-DMAC7.html)
Sweet et al. Methyldopa as an adjunct to levodopa treatment of Parkinson's disease
RU2002102076A (ru) Фармацевтическая композиция, содержащая сибутрамин и орлистат